Login to Your Account


BIVV-009 pivotal effort in CAgD

ATLANTA – Bioverativ Inc. wasted little time moving the monoclonal antibody (MAb) BIVV-009 into phase III development after picking up the complement C1s subcomponent inhibitor, previously known as TNT-009, in its potential $825 million acquisition of True North Therapeutics Inc. more »


Analysis

The Good Pharma Scorecard (GPS) released last week by the not-for-profit Bioethics International contained surprisingly good news. Two companies – Johnson & Johnson (J&J) and Sanofi SA – of 11 ranked on overall clinical trial transparency, based on drugs approved in 2014, achieved scores of 100 percent, tying them at the top of the list. Four others – Abbvie Inc., Celgene Corp., Merck & Co. Inc. and Astrazeneca plc – scored at or above the industry median of 91 percent.

read more »

Opinion


Partners in Focus